Mallinckrodt (NYSE: MNK) presented 11 posters with data on its investigational opioid, MNK-155, an extended-release oral formulation of hydrocodone and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE